What’s going on at the FDA? Novartis’ canakinumab setback and what to expect from detailed donanemab results

FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss the week’s most important news in pharma and biotech including suggestions that the FDA is suddenly taking a more cautious approach to some new drug approvals, negative data for Novartis’ canakinumab in second-line non-small cell lung cancer and a preview of detailed Phase II results for Eli Lilly’s Alzheimer’s disease drug donanemab, which will be presented this weekend at the AD/PD 2021 virtual congress.